← SynDRA
BICALUTAMIDE
SynDRA canonical compound SYN0000050 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | AR |
| Mechanism of action | Androgen receptor antagonist |
| Indication | prostate cancer |
| Disease area | oncology |
All known targets
Mechanisms of action (all sources)
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- GHSR
- NR1I2
- ESR1
- HTR6
- NPY2R
- NPY1R
- MLNR
- MC4R
- MC3R
- MAOA
- KCNH2
- HTR7
- ABCB11
- NR3C1
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- HRH1
- HDAC6
- HTR3A
- NTSR1
- OPRD1
- SLC6A2
- XPO1
- USP1
- TBXA2R
- TACR1
- SRD5A2
- SRD5A1
- SLC6A4
- SLC6A3
- SLC29A1
- OPRK1
- SCN5A
- SAMHD1
- PTGS2
- PTGS1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP2CJ
- CP3A4
- ESRRA
- KCMB1
- KCMB2
- NF2L2
- PRGR
Drug classes
- Androgen Receptor Antagonists
- Androgen Receptor Inhibitor
- Androgen Antagonists
- Antineoplastic Agents
- Hormone Antagonists
ATC classes
- L02B · HORMONE ANTAGONISTS AND RELATED AGENTS
- HORMONES AND RELATED AGENTS
Cross-references
Synonyms
- CASODEX
- Casodex
- ICI-176334
- casodex
- Bicalutamida
- ICI 176,334
- ICI176,334-1
- NSC-759816
- Calutide
- Cosudex
- Kalumid
- Propanamide
- Raffolutil
- Astra brand of bicalutamide
- AstraZeneca brand of bicalutamide
- Zeneca brand of bicalutamide
- Calutide (TN)
- Casodex (TN)
- Cosudex (TN)
- KS-1161
- Kalumid (TN)
- Bicalutamide [USAN:INN:BAN]
- Bicalutamide (JAN/USP/INN)
- Casodex, Cosudex, Calutide, Kalumid, Bicalutamide
- (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide
- Bicalutamide (CDX)
- A0Z3NAU9DP
- CHEMBL409
- NSC 759816
- SMR000466329
- SR-01000759410
- UNII-A0Z3NAU9DP
- BRN 5364666
- Bicalutamine
- Propanamide,
- CCRIS 8728
- HSDB 7655
Reported adverse events
- Asthenia
- Dyspepsia
- Rash
- Somnolence
- Constipation
- Flatulence
- Nausea
- Headache
- Nocturia
- Pneumonia
- Vomiting
- Alopecia
Look up BICALUTAMIDE in the interactive SynDRA portal →